These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 15974638)

  • 1. Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience.
    Hauser RA; Schwarzschild MA
    Drugs Aging; 2005; 22(6):471-82. PubMed ID: 15974638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Istradefylline: adenosine A2A receptor antagonist to reduce "OFF" time in Parkinson's disease.
    Paton DM
    Drugs Today (Barc); 2020 Feb; 56(2):125-134. PubMed ID: 32163528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.
    Kase H; Aoyama S; Ichimura M; Ikeda K; Ishii A; Kanda T; Koga K; Koike N; Kurokawa M; Kuwana Y; Mori A; Nakamura J; Nonaka H; Ochi M; Saki M; Shimada J; Shindou T; Shiozaki S; Suzuki F; Takeda M; Yanagawa K; Richardson PJ; Jenner P; Bedard P; Borrelli E; Hauser RA; Chase TN;
    Neurology; 2003 Dec; 61(11 Suppl 6):S97-100. PubMed ID: 14663020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An overview of adenosine A2A receptor antagonists in Parkinson's disease.
    Jenner P
    Int Rev Neurobiol; 2014; 119():71-86. PubMed ID: 25175961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).
    LeWitt PA; Guttman M; Tetrud JW; Tuite PJ; Mori A; Chaikin P; Sussman NM;
    Ann Neurol; 2008 Mar; 63(3):295-302. PubMed ID: 18306243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease.
    Jenner P
    Expert Opin Investig Drugs; 2005 Jun; 14(6):729-38. PubMed ID: 16004599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant.
    Perez-Lloret S; Merello M
    Expert Opin Pharmacother; 2014 Jun; 15(8):1097-107. PubMed ID: 24673462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of adenosine A2A receptor antagonist istradefylline as augmentation for Parkinson's disease: a meta-analysis of randomized controlled trials.
    Tao Y; Liang G
    Cell Biochem Biophys; 2015 Jan; 71(1):57-62. PubMed ID: 25096504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Istradefylline - a first generation adenosine A
    Jenner P; Mori A; Aradi SD; Hauser RA
    Expert Rev Neurother; 2021 Mar; 21(3):317-333. PubMed ID: 33507105
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson's Disease: A Pooled Analysis of 8 Phase 2b/3 Trials.
    Hauser RA; Hattori N; Fernandez H; Isaacson SH; Mochizuki H; Rascol O; Stocchi F; Li J; Mori A; Nakajima Y; Ristuccia R; LeWitt P
    J Parkinsons Dis; 2021; 11(4):1663-1675. PubMed ID: 34486986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued.
    Pinna A
    CNS Drugs; 2014 May; 28(5):455-74. PubMed ID: 24687255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the impact of adjunctive istradefylline on the cumulative dose of levodopa-containing medications in Parkinson's disease: study protocol for the ISTRA ADJUST PD randomized, controlled study.
    Hatano T; Kano O; Sengoku R; Yoritaka A; Suzuki K; Nishikawa N; Mukai Y; Nomura K; Yoshida N; Seki M; Matsukawa MK; Terashi H; Kimura K; Tashiro J; Hirano S; Murakami H; Joki H; Uchiyama T; Shimura H; Ogaki K; Fukae J; Tsuboi Y; Takahashi K; Yamamoto T; Yanagisawa N; Nagayama H
    BMC Neurol; 2022 Mar; 22(1):71. PubMed ID: 35241003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenosine A2A receptor antagonist istradefylline 20 versus 40 mg/day as augmentation for Parkinson's disease: a meta-analysis.
    Zhu C; Wang G; Li J; Chen L; Wang C; Wang Y; Lin P; Ran H
    Neurol Res; 2014 Nov; 36(11):1028-34. PubMed ID: 24725292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists.
    Pinna A; Wardas J; Simola N; Morelli M
    Life Sci; 2005 Nov; 77(26):3259-67. PubMed ID: 15979104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenosine A2A antagonists in Parkinson's disease: what's next?
    Hickey P; Stacy M
    Curr Neurol Neurosci Rep; 2012 Aug; 12(4):376-85. PubMed ID: 22585137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations.
    Müller T
    Expert Opin Drug Metab Toxicol; 2013 Aug; 9(8):1015-24. PubMed ID: 23642267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The belated US FDA approval of the adenosine A
    Chen JF; Cunha RA
    Purinergic Signal; 2020 Jun; 16(2):167-174. PubMed ID: 32236790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of istradefylline in the Parkinson's disease armamentarium.
    Müller T
    Expert Opin Pharmacother; 2023 May; 24(7):863-871. PubMed ID: 37029952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Occupancy of adenosine A
    Ishibashi K; Miura Y; Wagatsuma K; Toyohara J; Ishiwata K; Ishii K
    Neuropharmacology; 2018 Dec; 143():106-112. PubMed ID: 30253174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease.
    Mizuno Y; Kondo T;
    Mov Disord; 2013 Jul; 28(8):1138-41. PubMed ID: 23483627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.